News Sentiment

RANI sentiment intelligence

Rani Therapeutics Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.9% over one week, -9.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Rani Therapeutics Tries To Turn Biologic Shots Into Pills

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -10.9% Price reacting lower
Trend fit Trend inactive -9.6% over four weeks
Fair value -67.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 40
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 10
simplywall.st 6
GlobeNewswire 4
TradingView 4
Investing.com 2
Finimize 1
Quiver Quantitative 1

Event Lens

What the news is about

Classified themes
Market update 38
Earnings 13
Analyst action 3
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Stock Titan Direct company coverage

Rani Therapeutics (RANI) prices $20M stock and pre-funded warrant sale

Rani Therapeutics has priced a registered offering to raise approximately $20.0 million in gross proceeds through the sale of Class A common stock and pre-funded warrants. The offering includes over 12.4 million shares at $1.07 each and more than 6.2 million pre-funded warrants a

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 09:40
Source
Stock Titan
Investing.com UK Direct company coverage

Rani Therapeutics raises $20 million in direct offering

Rani Therapeutics Holdings Inc. announced a registered direct offering to raise approximately $20 million, selling Class A common stock and pre-funded warrants. The offering, led by a sovereign wealth fund, aims to boost the clinical-stage biotherapeutics company's capital despit

Tone
Negative 40/100
Event
Market update
Published
26 May 2026 18:40
Source
Investing.com UK
GlobeNewswire Direct company coverage

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

Rani Therapeutics Holdings, Inc. announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million. The offering, priced at-the-market under Nasdaq rules, involves a sovereign wealth fund and other healthcare-fo

Tone
Positive 66/100
Event
Market update
Published
26 May 2026 11:38
Source
GlobeNewswire
Stock Titan Direct company coverage

Sovereign wealth fund leads $20M raise for oral drug delivery firm

Rani Therapeutics announced a registered direct offering of Class A common stock and pre-funded warrants, expecting to raise approximately $20.0 million in gross proceeds. The financing, led by a sovereign wealth fund, involves the issuance of 12,476,637 shares and 6,214,953 pre-

Tone
Negative 39/100
Event
Market update
Published
26 May 2026 11:38
Source
Stock Titan
TipRanks Direct company coverage

Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price

Rani Therapeutics Holdings, Inc. Class A (RANI) is facing a Nasdaq delisting risk after receiving a deficiency notice for failing to maintain a $1.00 minimum bid price for 30 consecutive trading days. The company's Class A common stock could be delisted, which would severely impa

Tone
Neutral 50/100
Event
Market update
Published
17 May 2026 05:40
Source
TipRanks
Stock Titan Direct company coverage

Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition

Rani Therapeutics reported improved Q1 2026 financial results with increased contract revenue and a narrowed net loss, and expects its cash reserves to fund operations into Q4 2027. However, the company received a Nasdaq warning for failing to meet the minimum bid price requireme

Tone
Negative 38/100
Event
Earnings
Published
16 May 2026 11:42
Source
Stock Titan